Barbara Savoldo

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. pmc Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2620-30. 2007
  2. pmc Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
    Barbara Savoldo
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    Blood 108:2942-9. 2006
  3. pmc T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
    Antonio Di Stasi
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Blood 113:6392-402. 2009
  4. pmc Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
    Biagio De Angelis
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 114:4784-91. 2009
  5. pmc Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 110:2793-802. 2007
  6. pmc Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
    Kenneth P Micklethwaite
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
    Blood 115:2695-703. 2010
  7. ncbi request reprint Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Transplant 20:689-94. 2006
  8. ncbi request reprint Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Transplant 20:389-93. 2006
  9. pmc Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
    Chrystal U Louis
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
    Blood 118:6050-6. 2011
  10. pmc Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease
    Rikhia Chakraborty
    Center for Cell and Gene Therapy, Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Haematologica 98:533-7. 2013

Research Grants

  1. Improving Function and Persistence of Chimeric T Cells
    Barbara Savoldo; Fiscal Year: 2006
  2. Chimeric T Cell for Therpay of Hodgkin Disease
    Barbara Savoldo; Fiscal Year: 2010

Detail Information

Publications56

  1. pmc Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2620-30. 2007
    ..EBV-CTLs expressing both a native and a chimeric antigen receptor may therefore have added value for treatment of HD...
  2. pmc Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
    Barbara Savoldo
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    Blood 108:2942-9. 2006
    ..These data are consistent with an expansion and persistence of adoptively transferred EBV-CTLs that is limited in the presence of continued immunosuppression but that nonetheless produces clinically useful antiviral activity...
  3. pmc T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
    Antonio Di Stasi
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Blood 113:6392-402. 2009
    ..This approach may be of value in patients affected by HL...
  4. pmc Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
    Biagio De Angelis
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 114:4784-91. 2009
    ....
  5. pmc Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 110:2793-802. 2007
    ..We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach...
  6. pmc Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
    Kenneth P Micklethwaite
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
    Blood 115:2695-703. 2010
    ..This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse...
  7. ncbi request reprint Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Transplant 20:689-94. 2006
    ..Herein, we describe the use of a novel immune assay, which quantifies the lymphocyte immune response and correlates the value to risk for EBV infection...
  8. ncbi request reprint Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Transplant 20:389-93. 2006
    ..Herein we describe the use of cytokine polymorphisms and real-time quantitative polymerase chain reaction (qPCR) Epstein-Barr virus (EBV) viral load to identify patients at risk for PTLD development...
  9. pmc Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
    Chrystal U Louis
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
    Blood 118:6050-6. 2011
    ..This study is registered at www.clinialtrials.gov as #NCT00085930...
  10. pmc Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease
    Rikhia Chakraborty
    Center for Cell and Gene Therapy, Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Haematologica 98:533-7. 2013
    ....
  11. pmc Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma
    Serena K Perna
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Clin Cancer Res 19:106-17. 2013
    ..We used the model of adoptive transfer of Epstein-Barr virus (EBV)-CTLs, as these cells induce responses in patients with EBV-associated Hodgkin lymphoma, and Tregs are frequently abundant in these patients...
  12. pmc Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7
    Juan F Vera
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Mol Ther 17:880-8. 2009
    ..This approach may allow selective expansion of CTLs without the unwanted effects associated with IL-2...
  13. pmc Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
    Patrick J Hanley
    Department of Immunology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 114:1958-67. 2009
    ..This study is registered at www.clinicaltrials.gov as NCT00078533...
  14. ncbi request reprint Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients
    Timothy C Lee
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
    Am J Transplant 5:2222-8. 2005
    ..05). These findings illustrate that frequent EBV viral load monitoring and preemptive immunosuppression modulation have an integral role in preventing PTLD in the pediatric liver transplant population...
  15. pmc Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
    Conrad Russell Y Cruz
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
    Blood 122:2965-73. 2013
    ....
  16. pmc T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms
    Jiali Sun
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Ther 18:2006-17. 2010
    ..In conclusion, caAkt-transduced T cells showed resistance to several evasion strategies employed by tumors and may therefore enhance the antitumor activity of adoptively transferred T lymphocytes...
  17. pmc CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
    J Clin Invest 121:1822-6. 2011
    ....
  18. pmc Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
    Martin A Pule
    Center for Cell and Gene Therapy, Baylor College of Medicine and The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Nat Med 14:1264-70. 2008
    ..Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells...
  19. pmc Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 112:1876-85. 2008
    ..PRAME CTLs were generated almost exclusively from the naive T-cell compartment, and clonal analysis showed these cells could have high alphabetaTCR-peptide avidity. PRAME CTLs or vaccines may thus be of value for patients with CML...
  20. ncbi request reprint Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection
    Barbara Savoldo
    Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 100:4059-66. 2002
    ....
  21. pmc T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
    Juan Vera
    Center for Cell and Gene Therapy, Baylor College of Medicine, Fannin St, MC 3 3320, Houston, TX 77030, USA
    Blood 108:3890-7. 2006
    ....
  22. pmc Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination
    Leslie E Huye
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Ther 19:2239-48. 2011
    ..CD19-28ζ T cells or rapa alone. In conclusion, the combination of rapa and rapa-resistant, CAR.CD19-28ζ-expressing T cells may provide a novel therapy for the treatment of B cell malignancies and other cancers...
  23. pmc Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma
    Ulrike Gerdemann
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, Texas 77030, USA
    Mol Ther 19:2258-68. 2011
    ..Infusion of such multispecific monocultures may extend the benefits of CTL therapy to treatment even of EBV negative HL and NHL...
  24. ncbi request reprint Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas
    Zhensheng Liu
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Recent Results Cancer Res 159:123-33. 2002
    ....
  25. ncbi request reprint Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, Texas, USA
    Am J Transplant 5:566-72. 2005
    ..Rituximab effectively induced regression of PTLD in OLT recipients. However, EBV-specific T-cell immunocompetence, which may be crucial for the long-term control of EBV-mediated proliferation, did not improve...
  26. pmc Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice
    Simon N Robinson
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 40:445-56. 2012
    ..We propose that ex vivo fucosylation will similarly improve the rate and magnitude of engraftment for CB transplant recipients in a clinical setting...
  27. pmc Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, 77030 USA
    Mol Cancer 8:106. 2009
    ..This outcome supports the presence of a rare population of precursor/progenitor cells in human malignancies, and suggests benefit from their removal...
  28. pmc High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 117:3353-62. 2011
    ..These PRAME-directed CTLs did not affect normal hematopoietic progenitors, indicating that this approach may be of value for immunotherapy of PRAME(+) hematologic malignancies...
  29. pmc Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?"
    Gianpietro Dotti
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital, Houston, TX 77030, USA
    Hum Gene Ther 20:1229-39. 2009
    ..In this review we summarize the concept of CAR-based immunotherapy, describe the steps accomplished, and outline the future progress we need to make if this approach is truly to improve cancer immunotherapy...
  30. pmc T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
    Donald R Shaffer
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX 77030, USA
    Blood 117:4304-14. 2011
    ..Adoptively transferred CD70-specific T cells induced sustained regression of established murine xenografts. Therefore, CD70-specific T cells may be a promising immunotherapeutic approach for CD70-positive malignancies...
  31. pmc Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells
    Eric Yvon
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Cancer Res 15:5852-60. 2009
    ..Moreover, these transgenic receptors can be directed to tumor-associated antigens that are not protein-derived, such as the ganglioside GD2, which is expressed in a high proportion of melanoma cells...
  32. doi request reprint Gene therapy to improve migration of T cells to the tumor site
    Antonio Di Stasi
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Methods Mol Biol 651:103-18. 2010
    ....
  33. pmc Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes
    Sujatha Muralidharan
    Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunol 187:5221-32. 2011
    ..The arrest in T cell differentiation induced by Wnt signaling might have relevant clinical applications such as to preserve the naive T cell compartment in Ag-specific T cells generated ex vivo for adoptive T cell immunotherapy...
  34. doi request reprint Gene therapy to improve function of T cells for adoptive immunotherapy
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Methods Mol Biol 651:119-30. 2010
    ..We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach...
  35. ncbi request reprint Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Acta Haematol 110:139-48. 2003
    ..The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated...
  36. ncbi request reprint Targeted delivery of adenoviral vectors by cytotoxic T cells
    Patricia Yotnda
    Center for Cell and Gene Therapy, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    Blood 104:2272-80. 2004
    ....
  37. ncbi request reprint Regression of experimental medulloblastoma following transfer of HER2-specific T cells
    Nabil Ahmed
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, The Methodist Hospital, Houston, Texas 77030, USA
    Cancer Res 67:5957-64. 2007
    ..In contrast, delivery of nontransduced T cells did not change the tumor growth pattern. Adoptive transfer of HER2-specific T cells may represent a promising immunotherapeutic approach for medulloblastoma...
  38. ncbi request reprint Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hosptial and Texas Children s Hospital, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 17:401-13. 2004
    ..The use of genetically modified T cells or newer suicide genes may result in improved safety and efficacy. Current challenges are to define indications for immunotherapy or antibody therapy in patients with incipient or overt PTLD...
  39. doi request reprint Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition
    Serena K Perna
    Authors Affiliations Center for Cell and Gene Therapy, and Departments of Pediatrics, Immunology, and Medicine, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, Texas Dipartimento di Ematologia ed Oncologia Pediatrica, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
    Clin Cancer Res 20:131-9. 2014
    ....
  40. pmc Inducible apoptosis as a safety switch for adoptive cell therapy
    Antonio Di Stasi
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX 77030, USA
    N Engl J Med 365:1673-83. 2011
    ..When exposed to a synthetic dimerizing drug, the inducible caspase 9 (iCasp9) becomes activated and leads to the rapid death of cells expressing this construct...
  41. pmc Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
    Gianpietro Dotti
    Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    Blood 105:4677-84. 2005
    ..EBV-CTLs with knocked down Fas should have a selective functional and survival advantage over unmodified EBV-CTLs in the presence of tumors expressing FasL and may be of value for adoptive cellular therapy...
  42. pmc Genetic modification of human T lymphocytes for the treatment of hematologic malignancies
    Valentina Hoyos
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Haematologica 97:1622-31. 2012
    ..This review summarizes the most recent biological and clinical developments using genetically manipulated T cells for the treatment of hematologic malignancies...
  43. pmc Changes in chemokine receptor expression of regulatory T cells after ex vivo culture
    Rikhia Chakraborty
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    J Immunother 35:329-36. 2012
    ..Our analyses suggest that ex vivo cultured Tregs may display impaired or suboptimal migration to the inflamed tissues releasing RANTES and MIP-1α chemokines...
  44. ncbi request reprint Immunotherapy for post-transplant lymphoproliferative disease
    Karin C M Straathof
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Br J Haematol 118:728-40. 2002
  45. ncbi request reprint Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications
    Ann M Leen
    Center for Cell and Gene Therapy, Department of Pediatrics, 6621 Fannin S, MC 3 3320, Houston, TX 77030, USA
    Blood 103:1011-9. 2004
    ..This is the first report of a simple and reproducible method to activate and expand Ad-specific cytotoxic T lymphocytes (CTLs), which should be protective against the range of different Ad subtypes that affect transplant recipients...
  46. doi request reprint T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
    Claudia Geldres
    Authors Affiliations Center for Cell and Gene Therapy Departments of Pediatrics, Pathology and Immunology, and Medicine, Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine Houston Methodist Hospital and Texas Children s Hospital Department of Surgery, Michael E DeBakey Department of Veterans Affairs Medical Center Dan L Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, Texas and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 20:962-71. 2014
    ..We tested whether T cells transduced with a CSPG4-specific chimeric antigen receptor (CAR) inhibited the growth of CSPG4-expressing tumor cells both in vitro and in vivo...
  47. pmc Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies
    Carlos A Ramos
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX77030, USA
    J Immunother 36:66-76. 2013
    ..Because our technique is scalable and good-manufacturing procedures-compliant, these lines could be used for adoptive cellular immunotherapy of patients with HPV16 cancers...
  48. pmc Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience
    Conrad Russell Cruz
    Dan L Duncan Cancer Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, Texas 77030, USA
    Cytotherapy 12:743-9. 2010
    ..Recent catastrophic reactions to 'first-in-man' biologic agents have emphasized the importance of this rule for initial studies of new products. The value of such monitoring for better established agents is less obvious...
  49. pmc Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells
    David Steiner
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Stem Cells 27:1932-40. 2009
    ..The results suggest that multipotent stem cells can be expanded ex vivo and can contribute meaningfully to long-term hematopoietic engraftment...
  50. pmc Design and development of therapies using chimeric antigen receptor-expressing T cells
    Gianpietro Dotti
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Immunol Rev 257:107-26. 2014
    ....
  51. ncbi request reprint Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals
    Barbara Savoldo
    Center for Cell and Gene Therapy and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunol 168:909-18. 2002
    ..In addition, our method for selecting EBV-specific CTL from naive individuals by precursor cell enrichment may be applicable to the immunotherapy of cancer patients with a low frequency of tumor- or virus-specific CTL...
  52. ncbi request reprint Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells
    Gianpietro Dotti
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 100:200-7. 2002
    ..Hence, transgenic CD40L expression may produce an antimyeloma immune response against either CD40(+) or CD40(-) tumors and may be of therapeutic value for both types of myeloma in humans...
  53. doi request reprint Genetic modification of cytotoxic T lymphocytes to express cytokine receptors
    Serena K Perna
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Methods Mol Biol 1139:189-200. 2014
    ..In this chapter, we describe the methodology to obtain the ectopic expression of IL-7 receptor alpha (IL-7Rα) in antigen-specific CTL, using Epstein-Barr virus-specific CTL (EBV-CTL), as a model. ..
  54. ncbi request reprint What influence has B-cell depletion on viral infections?
    Anjum S Kaka
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
    Leuk Lymphoma 48:1257-8. 2007
  55. pmc PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation
    Wenjing Sun
    Texas Children s Cancer Center, Department of Pediatrics, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, United States
    Cell Signal 21:95-102. 2009
    ..These data suggest that PPM1A and PPM1B play an important role in the termination of TNFalpha-mediated NF-kappaB activation through dephosphorylating and inactivating IKKbeta...
  56. doi request reprint Chimeric antigen receptors (CARs) from bench-to-bedside
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA Department of Pediatrics, Texas Children s Hospital, Houston, TX 77030, USA
    Immunol Lett 155:40-2. 2013
    ..In this brief review, we outline some specific aspects that have led to antitumor responses in cancer patients. ..

Research Grants4

  1. Improving Function and Persistence of Chimeric T Cells
    Barbara Savoldo; Fiscal Year: 2006
    ..The data produced by this project will be crucial to develop appropriate clinical trails with redirected T cells. ..
  2. Chimeric T Cell for Therpay of Hodgkin Disease
    Barbara Savoldo; Fiscal Year: 2010
    ..We now want to extend the application of this promising treatment by targeting other proteins that are on all HD cells, and by making the immune cells more potent. ..